ATH 3.45% 2.8¢ alterity therapeutics limited

+ + data and comment + +

  1. 22,691 Posts.
    7.15 mill shares issued at 70 cents and about $5 mil was raised taking cash holdings to $7 mill.:


    "On 5 August 2003 Prana announced that its highly successful medicinal chemistry program had created a library of approx. 300 compounds specifically engineered to address age-related neurodegenerative diseases such as Alzheimers Disease.

    From these compounds the Company’s technical review committee selected an NCE (New Chemical Entity) which has been code-named

    PBT-2 to advance to human clinical trials. This follows the successful completion of Prana’s recent proof of concept trial utilising clioquinol (PBT-1), an existing off-label drug previously prescribed for a non-related application.

    PBT-2 is a new proprietary compound developed by Prana scientists to specifically target Alzheimers Disease.

    It is owned exclusively by Prana and has significantly outperformed PBT-1 in the laboratory and animal trials undertaken to date.

    Given the success of the previous human trials of PBT-1 the Board of Prana and its scientists approach the clinical phase of PBT-2 with heightened confidence".
watchlist Created with Sketch. Add ATH (ASX) to my watchlist
(20min delay)
Mkt cap ! $58.35M
Open High Low Value Volume
3.0¢ 3.0¢ 2.8¢ $387.8K 13.49M

Buyers (Bids)

No. Vol. Price($)
39 11726381 2.8¢

Sellers (Offers)

Price($) Vol. No.
2.9¢ 1881814 8
View Market Depth
Last trade - 16.10pm 06/05/2021 (20 minute delay) ?
-0.001 ( 5.08 %)
Open High Low Volume
2.9¢ 2.9¢ 2.8¢ 6201460
Last updated 15.59pm 06/05/2021 (live) ?
ATH (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.